KDR and hepatocellular carcinoma: Next, we assessed other MTAs, including anti-VEGFR-2 antibody (used in the same manner as ramucirumab in humans), regorafenib, and cabozantinib, which have been approved as second-line drugs for the treatment of advanced HCC.